View DividendHyper マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Mar 17Less than half of directors are independent Jun 26Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Mar 18Less than half of directors are independent Nov 16Less than half of directors are independent Apr 27すべての更新を表示Recent updatesNew major risk - Financial position Apr 03New major risk - Shareholder dilution Mar 26Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Mar 17Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion.Feb 27Hyper Corporation Inc. announced that it has received KRW 34.999990179 billion in funding from UTXO Management GP, LLC, Fundpartner Solutions (Europe) SA, Woori Technology Investment Co., Ltd, Fanatic Strategic Holdings Pte. Ltd., Walkers Corporate Limited, Investment Arm, Kingsway Capital Partners LimitedDec 31Is Hyper (KOSDAQ:065650) A Risky Investment?Dec 01New major risk - Share price stability Nov 14Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion.Sep 17New minor risk - Financial data availability Aug 30An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion.Aug 08We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of DebtJun 26Less than half of directors are independent Jun 26Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Mar 18New minor risk - Share price stability Feb 04Medifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270).Jun 01+ 2 more updatesNew major risk - Shareholder dilution May 10Medifron DBT Co., Ltd. announced that it has received KRW 20.999999826 billion in funding from FSN Co., Ltd.Apr 27Medifron DBT Co., Ltd. announced that it expects to receive KRW 41.999999652 billion in fundingFeb 17Medifron DBT Co., Ltd. announced that it expects to receive KRW 20.999999826 billion in funding from FSN Co., Ltd.Feb 16New minor risk - Share price stability Feb 16New major risk - Share price stability Jul 12Medifron DBT Co., Ltd. announced that it has received KRW 4.0000092 billion in funding from T Scientific Co.,LtdDec 15Less than half of directors are independent Nov 16Medifron DBT Co., Ltd. announced that it has received KRW 3 billion in fundingAug 26Medifron DBT Co., Ltd. announced that it expects to receive KRW 3 billion in fundingAug 24Medifron DBT Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Shinhan Financial Investment Co., Ltd., Mirae Asset Securities Co. Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd.Jun 23+ 2 more updatesLess than half of directors are independent Apr 27Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?Mar 15New 90-day low: ₩3,480 Mar 08Medifron DBT Co., Ltd. announced that it has received KRW 14.99999874 billion in funding from T Scientific Co., Ltd.Feb 06New 90-day low: ₩3,620 Jan 28New 90-day low: ₩3,985 Dec 18Medifron DBT Co., Ltd. announced that it expects to receive KRW 8 billion in fundingDec 02Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its DebtNov 29New 90-day low: ₩4,460 Oct 19Medifron DBT Co., Ltd. announced that it has received KRW 20 billion in funding from T.S. Investment CorporationSep 03Medifron DBT Co., Ltd. announced that it expects to receive KRW 20 billion in funding from T.S. Investment CorporationAug 26CEOHyper CEOがいない、あるいは彼らに関するデータがない。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 03:26終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hyper Corporation Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関NaYeon KimMirae Asset Securities Co., Ltd.
Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion.Feb 27
Hyper Corporation Inc. announced that it has received KRW 34.999990179 billion in funding from UTXO Management GP, LLC, Fundpartner Solutions (Europe) SA, Woori Technology Investment Co., Ltd, Fanatic Strategic Holdings Pte. Ltd., Walkers Corporate Limited, Investment Arm, Kingsway Capital Partners LimitedDec 31
Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion.Sep 17
An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion.Aug 08
Medifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270).Jun 01+ 2 more updates
Medifron DBT Co., Ltd. announced that it has received KRW 20.999999826 billion in funding from FSN Co., Ltd.Apr 27
Medifron DBT Co., Ltd. announced that it expects to receive KRW 41.999999652 billion in fundingFeb 17
Medifron DBT Co., Ltd. announced that it expects to receive KRW 20.999999826 billion in funding from FSN Co., Ltd.Feb 16
Medifron DBT Co., Ltd. announced that it has received KRW 4.0000092 billion in funding from T Scientific Co.,LtdDec 15
Medifron DBT Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Shinhan Financial Investment Co., Ltd., Mirae Asset Securities Co. Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd.Jun 23+ 2 more updates
Medifron DBT Co., Ltd. announced that it has received KRW 14.99999874 billion in funding from T Scientific Co., Ltd.Feb 06
Medifron DBT Co., Ltd. announced that it has received KRW 20 billion in funding from T.S. Investment CorporationSep 03
Medifron DBT Co., Ltd. announced that it expects to receive KRW 20 billion in funding from T.S. Investment CorporationAug 26
